Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...
Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...
Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted)NEW YORK, ...
In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with ...
Major pathologic response serves as a key factor in determining subsequent adjuvant ... compared with pembrolizumab monotherapy in patients with high-risk, resected stage III melanoma while ...
A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...
for untreated unresectable locally advanced non-small-cell lung cancer [ID6399] Technology appraisal guidance Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback